Free
Meeting Abstracts  |   July 2002
Volatile Anesthetics Mimic Cardiac Preconditioning by Priming the Activation of Mitochondrial KATPChannels via  Multiple Signaling Pathways
Author Affiliations & Notes
  • Michael Zaugg, M.D., D.E.A.A.
    *
  • Eliana Lucchinetti, M.S.
  • Donat R. Spahn, M.D.
  • Thomas Pasch, M.D.
    §
  • Marcus C. Schaub, M.D., Ph.D.
  • *Attending Physician, †Research Associate, §Professor and Chairman, Institute of Anesthesiology, University Hospital Zurich. ‡Professor and Chairman, Department of Anesthesiology, University Hospital Lausanne. ∥Professor of Pharmacology, Department of Pharmacology and Toxicology, University of Zurich.
  • Received from the Institute of Anesthesiology, University Hospital Zurich, Zurich, Switzerland; the Department of Anesthesiology, University Hospital Lausanne, Lausanne, Switzerland; and the Department of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.
Article Information
Meeting Abstracts   |   July 2002
Volatile Anesthetics Mimic Cardiac Preconditioning by Priming the Activation of Mitochondrial KATPChannels via  Multiple Signaling Pathways
Anesthesiology 7 2002, Vol.97, 4-14. doi:
Anesthesiology 7 2002, Vol.97, 4-14. doi:
PRECONDITIONING is a most powerful mode of reducing myocardial infarction size after ischemia and has been established in every species and experimental model in which it was evaluated. 1 It represents an adaptive endogenous response to brief sublethal episodes of ischemia or to pharmacological interventions leading to paradoxical pronounced protection against subsequent lethal ischemia. Pharmacological induction of preconditioning, in contrast to classic ischemic preconditioning, would therefore be greatly desirable, specifically in high-risk patients in whom an ischemic-type of preconditioning may further jeopardize diseased myocardium.
Volatile anesthetics, which are known to improve postischemic recovery 2 and to decrease myocardial infarction size, 3 effectively activate protective cellular mechanisms. Notably, the protective effect of volatile anesthetics even occurs in the presence of already established cardioplegic protection. 4,5 To date, a substantial body of evidence implicates adenosine triphosphate–sensitive potassium (KATP) channels as playing a pivotal role in the acquisition of the preconditioned state in the heart and proposes opening of this channel as the final common step underlying all preconditioned-like states, including those elicited by volatile anesthetics. 6,7 Although a preponderance of studies point to mitochondrial rather than sarcolemmal channels as likely players in preconditioning, 8 so far it is not clear whether opening of the sarcolemmal KATP(sarcKATP) channel or the mitochondrial KATP(mitoKATP) channel is more important in mediating anesthetic-induced preconditioning. 9 Furthermore, while results from patch clamp experiments demonstrate increased open probability of the sarcKATPchannel for a given ATP concentration in response to isoflurane, 10 no such data are available regarding the effects of volatile anesthetics on the activity of the mitoKATPchannel, the proposed final effector of preconditioning. Therefore, the purpose of this study was to determine the protective effects of sarcKATPchannels and mitoKATPchannels in mediating cardioprotection by volatile anesthetics as well as the signaling pathways involved, and to test whether volatile anesthetics directly open mitoKATPchannels.
Materials and Methods
This study was performed in accordance with the guidelines of the Animal Care and Use Committee of the University of Zurich.
Preparation of Isolated Rat Ventricular Myocytes
Ca2+-tolerant adult rat ventricular myocytes were isolated from hearts of male Sprague-Dawley rats (300 g) as previously described. 11 Thirty minutes prior to decapitation, animals were heparinized (500 units administered intraperitoneally). To avoid any putative effects on KATPchannel activity, 12,13 no anesthetics were used. The hearts were quickly removed into a 4°C HEPES-buffered solution (117 mm NaCl, 5.7 mm KCl, 1.5 mm NaH2PO4, 4.4 mm NaHCO3, 20 mm HEPES, 10 mm glucose, 10 mm creatine, at pH 7.4) containing 1.8 mm Ca2+and then perfused on a Langendorff apparatus for 5 min at 37°C gassed with oxygen. The perfusion solution was switched to a nominally Ca2+-free solution containing 0.1 mm EGTA for 7 min and then to a nominally Ca2+-free solution containing 0.15% collagenase A (Roche, Mannheim, Germany). After 30 min of digestion, the enzymatic solution was washed out, and the tissue from the left ventricle was cut into small pieces and gently swirled in the HEPES-buffered solution containing 0.125 mm Ca2+. Dissociated cells were filtered through a 200-μm mesh and allowed to settle for 20 min. The cells were then resuspended in the buffered solution containing 5 mg/ml BSA and exposed to a graded series of increasing Ca2+concentrations up to 1.8 mm. Each step was followed by a gentle centrifugation with less than 20 g  for 2 min to separate the ventricular myocytes from nonmyocytes. The isolated myocytes were resuspended in serum-free defined culture medium consisting of DMEM with 2 mg/ml BSA, 2 mm l-carnitine, 5 mm creatine, and 5 mm taurine. Notably, to avoid any putative effect on KATPchannels, no antibiotics were added to culture medium. Cells were incubated for 3 h before experiments to allow reestablishment of normal electrolyte gradients. Purity of cardiomyocyte cultures was assessed by determining the percentage of myosin positive–staining cells using immunofluorescence with a myosin heavy chain specific antibody, MF-20, as previously described. Ninety-nine percent of cells stained positive. 11 
Measurement of Flavoprotein Fluorescence
The fluorescence of FAD-linked enzymes, called flavoproteins, was used to monitor mitochondrial redox state, which is a direct indicator of mitoKATPchannel activity. 14,15 Isolated myocytes were cultured at a density of 100–150 cells/mm2on 20 mm round glass coverslips precoated with laminin (1 μg/cm2; Sigma, St. Louis, MO) placed in 35-mm plastic culture dishes. After 2 h, the dishes were washed with phosphate-buffered saline to remove cells that were not attached. Experiments were performed over the next 12 h. The treatment protocols and the concentrations of the reagents used were established previously. 16,17 Myocytes on glass coverslips were placed in a customized airtight perfusion chamber with a volume of 0.5 ml, covered with a 25-mm glass coverslip, which was tightly sealed with vacuum grease (Fisher, Pittsburgh, PA) and perfused at room temperature (25°C) with a buffer solution at a flow rate of 0.5 ml/min containing (pH 7.4) 140 mm NaCl, 5 mm KCl, 1 mm MgCl2, 1.8 mm CaCl2, and 10 mm HEPES. Myocytes were exposed in series to the following solutions: plain buffer solution (baseline), buffer with 100 μm diazoxide (Biomol, Plymouth Meeting, PA) followed by a washout with plain buffer, buffer saturated with sevoflurane or isoflurane (Abbott AG, Baar, Switzerland) in the presence or absence of 2 μm chelerythrine (Biomol) for 10 min followed by a washout with plain buffer, and finally buffer with 100 μm 2,4-dinitrophenol (Sigma, St. Louis, MO). Buffer solution was equilibrated with 2.8% (vol/vol) sevoflurane or 1.2% (vol/vol) isoflurane using a Sevotec 5 vaporizer (Datex-Ohmeda, Tewksbury, MA) or an Isotec 3 vaporizer (Datex-Ohmeda), respectively, with an air bubbler. Delivered vapor concentrations of the volatile anesthetics were continuously controlled by the infrared gas analyzer Capnomac Ultima (Datex-Ohmeda). Applied concentrations of sevoflurane and isoflurane were also measured in the buffer solution of the perfusion chamber using a gas chromatograph (Perkin-Elmer, Norwalk, CT): sevoflurane 2.8% (vol/vol) (2 minimum alveolar concentration [MAC] in rats at 25°C) 0.92 ± 0.01 mm, isoflurane 1.2% (vol/vol) (2 MAC in rats at 25°C) 0.63 ± 0.01 mm. Chelerythrine was dissolved in buffer at a concentration of 2 μm. Diazoxide was dissolved at 100 μm in buffer solution containing dimethyl sulfoxide (DMSO) 0.1%. Because DMSO was used as a solvent for diazoxide, a series of experiments was studied in which DMSO alone was administered to myocytes. Importantly, DMSO alone at the concentration used in the experiments had no effect on autofluorescence of myocytes (data not shown). Also, separate experiments showed that chelerythrine (2 μm) alone or followed by diazoxide did not affect autofluorescence of flavoproteins (see Results section). For each experimental group, myocytes of 8 different rat hearts were used (n = 8), and all experiments were performed in duplicate. Data from one heart were averaged. An upright microscope (Axioplan2; Zeiss, Jena, Germany) equipped with a xenon arc lamp and the appropriate filter set (excitation at 480 nm, emission at 530 nm) was used to monitor the autofluorescence of myocytes. Images were captured using a cooled CCD camera (ORCA-100, 12 bit digital output; Hamamatsu Photonics, Herrsching, Germany) controlled by an image acquisition software (Openlab; Improvision, Lexington, MA). Fluorescence intensity was recorded every 15 s by exposing myocytes for 125 ms using a computer-controlled high-speed shutter (Openlab; Improvision). Calibration of flavoprotein fluorescence was achieved by setting fluorescence obtained after 2,4-dinitrophenol exposure to 100%. 2,4-Dinitrophenol uncouples oxidative phosphorylation and subsequently leads to fully oxidized flavoproteins. All measurements of flavoprotein oxidation were then expressed as percentage of 2,4-dinitrophenol–induced maximal autofluorescence. In each experiment, the fluorescence of 5–10 myocytes was monitored with a 20× objective lens (LD Achroplane, NA = 0.4; Zeiss). Processing of the flavoprotein signals was achieved using a binary mask, which was separately drawn for each myocyte using Openlab software (Improvision). This allowed exclusion of artifacts from other myocytes and background, and the time course of flavoprotein fluorescence of multiple individual myocytes could be selectively and simultaneously traced. A pseudocolor palette was finally used to visualize the relative intensity of mitochondrial flavoprotein oxidation states. Myocytes with an increased initial autofluorescence greater than 30% of the peak 2,4-dinitrophenol–induced autofluorescence were excluded from analysis and considered as damaged cells.
Simulated Ischemia in Cardiomyocytes
Myocytes were suspended in the incubation buffer containing 119 mm NaCl, 25 mm NaHCO3, 1.2 mm KH2PO4, 4.8 mm KCl, 1.2 mm MgSO4, 1.8 mm CaCl2, 10 mm HEPES, 11 mm glucose, 24.9 mm creatine, and 58.5 mm taurine and supplemented with 1% basal medium Eagle amino acids (GIBCO, Paisley, Scotland, UK) and 1% minimum essential medium nonessential amino acids (Sigma) at pH 7.4. Volatile anesthetics at 0.5, 1.0, 1.5, and 2.0 MAC were administered to myocytes for 15 min before simulated ischemia by gently bubbling a 10-ml tube in a standard incubator at 37°C, at the bottom of which 1.5 ml of a myocyte suspension was placed. Control samples were only gassed with air. Applied concentrations were continuously monitored and in addition measured by gas chromatography: sevoflurane: 0.5 MAC 0.22 ± 0.02 mm, 1.0 MAC (2.5%[vol/vol]) 0.50 ± 0.03 mm, 1.5 MAC 0.71 ± 0.01 mm, 2.0 MAC 0.96 ± 0.01 mm; isoflurane: 0.5 MAC 0.16 ± 0.02 mm, 1 MAC (1.4%[vol/vol]) 0.34 ± 0.02 mm, 1.5 MAC 0.50 ± 0.02 mm, 2 MAC 0.72 ± 0.01 mm. In separate experiments, for each of the drugs listed below, dose–response curves with respect to myocyte death were established in the presence and absence of volatile anesthetics to determine the optimum concentration, which guaranteed the maximum inhibitory or stimulatory effect on the specific signal transduction component under investigation. Accordingly, depending on the treatment group, myocytes were exposed to 100 μm 8-sulfophenyl theophylline, 100 μm 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), 100 μm adenosine, 0.1 μm prazosin, 5 μm propranolol, 2 μm chelerythrine, 100 μm 5-hydroxydecanoate (all drugs purchased from Sigma), 50 μm HMR-1098 (a gift from Aventis AG, Frankfurt am Main, Germany), 100 μm 2-(4-carboxyphenyl)-4,4′,5,5′-tetramethylimidazole-1-oxyl-3-oxide (PTIO), 1 μg/ml pertussis toxin (PTX), 50 μm N  G-nitro-l-arginine methyl ester (l-NAME), 50 μm l-N6-(1-iminoethyl)lysine (l-NIL), 1 mm 8-bromo-cGMP, and 100 μm S  -nitroso-N  -acetyl-dl-penicillamine (SNAP) (all drugs purchased from Biomol). Drugs were administered 20 min prior to simulated ischemia and 5 min prior to administration of volatile anesthetics, respectively, except for PTX, which was added to myocytes 2 h before ischemia. Diazoxide, adenosine, SPT, SNAP, and PTIO were dissolved in DMSO containing buffer solution (final concentration of DMSO 0.1%). Because DMSO was used as a solvent for these drugs, a series of experiments was performed in which DMSO alone was administered to myocytes. DMSO alone, at the concentration used in the experiments, had no effect on survival of myocytes. In separate experiments diazoxide was administered at 1 μm, 10 μm, and 100 μm in the presence and absence of 1 MAC sevoflurane or isoflurane 15 min before 120 min of ischemia. After the various treatment modalities, 1 ml of the myocyte suspension was pipetted from the bottom of the 10-ml tube into a 1.5-ml microcentrifuge tube and centrifuged for 20 s at 15 g  . The supernatant was discarded, and 0.25 ml of mineral oil (Sigma) was layered onto the myocyte pellet to inhibit gaseous diffusion of oxygen, as previously described. 17,18 Following 60 and 120 min of incubation in a standard incubator at 37°C, 15 μl of myocytes was sampled through the mineral oil layer and mixed with 150 μl of a hypotonic trypan blue staining solution containing 11.9 mm NaHCO3, 0.4 mm KH2PO4, 2.7 mm KCl, 0.8 mm MgSO4, 1.8 mm CaCl2, 0.5% glutaraldehyde, and 0.5% trypan blue. 19,20 In the various protocols, for each experimental group, cells of 8 different rat hearts (n = 8) were used, and experiments were performed in duplicate. Myocyte viability was assessed by counting the number of myocytes staining clearly after 3 min of exposure to the hypoosmolar trypan blue staining solution. Myocytes, which stained dark blue, were considered irreversibly damaged. Five randomly chosen fields (1 mm2) were counted at 10 × 10 magnification with a phase-contrast microscope in duplicate and expressed as the percentage of total viable myocytes before ischemia. The percentage of myocytes viable at the beginning of the experiments was 90 ± 3% (n = 30). The small percentage of nonviable myocytes was due to the enzymatic isolation procedure. Importantly, the number of viable cells remained unchanged in untreated myocytes over the 1- or 2-h period of the experiments, and administration of volatile anesthetics did not affect myocyte viability over this period. Also, in the preparation used, the myocytes excluded trypan blue and retained their rod-shaped configurations over a 6-h period following isolation (89 ± 4%, n = 30).
Statistical Analysis
Data are expressed as mean ± SD. Analysis of variance with post hoc  Scheffé test for multiple comparisons was performed to determine statistical significance of multiple treatments. P  < 0.05 was considered to be significant (StatView Version 4.5; Abacus Concepts, Berkeley, CA).
Results
Volatile Anesthetics Preserve Myocyte Viability Dose-Dependently in a Cellular Model of Simulated Ischemia
To evaluate the potency of sevoflurane and isoflurane to protect myocytes from undergoing irreversible ischemic damage, isolated myocytes were exposed to increasing concentrations of sevoflurane and isoflurane (0.5 MAC, 1 MAC, 1.5 MAC, 2.0 MAC) 15 min before 60 or 120 min of ischemia. Cellular injury was determined by counting myocytes, which were not capable of excluding trypan blue staining under hypotonic conditions. Both volatile anesthetics dose-dependently reduced the percentage of trypan blue–positive myocytes, with isoflurane slightly more effective than sevoflurane at equipotent MAC values (fig. 1). After 120 min of ischemia, pretreatment of myocytes with 2 MAC sevoflurane and isoflurane decreased the percentage of trypan blue–positive myocytes markedly, from 67 ± 5% to 30 ± 3% and 26 ± 3%, respectively (P  < 0.0001, n = 8). Importantly, no substantial further protection was achieved by sevoflurane and isoflurane with MAC values greater than 1.5.
Fig. 1. Dose-dependent protection by sevoflurane (SEVO) and isoflurane (ISO) in myocytes exposed to 60 or 120 min of ischemia. The number of myocytes stained with trypan blue is indicated as percentage of total viable myocytes before ischemia. Data are mean ± SD. MAC = minimum alveolar concentration; CTL = control group. *P  < 0.001, any bar of SEVO- or ISO-treated myocytes versus  the respective CTL bar or the respec-tive bar at the preceding lower MAC value. #P  not significant, bar of SEVO- or ISO-treated myocytes at 2.0 MAC versus  the respective bar at 1.5 MAC.
Fig. 1. Dose-dependent protection by sevoflurane (SEVO) and isoflurane (ISO) in myocytes exposed to 60 or 120 min of ischemia. The number of myocytes stained with trypan blue is indicated as percentage of total viable myocytes before ischemia. Data are mean ± SD. MAC = minimum alveolar concentration; CTL = control group. *P 
	< 0.001, any bar of SEVO- or ISO-treated myocytes versus 
	the respective CTL bar or the respec-tive bar at the preceding lower MAC value. #P 
	not significant, bar of SEVO- or ISO-treated myocytes at 2.0 MAC versus 
	the respective bar at 1.5 MAC.
Fig. 1. Dose-dependent protection by sevoflurane (SEVO) and isoflurane (ISO) in myocytes exposed to 60 or 120 min of ischemia. The number of myocytes stained with trypan blue is indicated as percentage of total viable myocytes before ischemia. Data are mean ± SD. MAC = minimum alveolar concentration; CTL = control group. *P  < 0.001, any bar of SEVO- or ISO-treated myocytes versus  the respective CTL bar or the respec-tive bar at the preceding lower MAC value. #P  not significant, bar of SEVO- or ISO-treated myocytes at 2.0 MAC versus  the respective bar at 1.5 MAC.
×
Myocyte Protection by Volatile Anesthetics is Selectively Mediated by Mitochondrial KATPChannels
To test whether isoflurane- and sevoflurane-induced protection in myocytes is mediated by the sarcKATPchannel or the mitoKATPchannel, myocytes were exposed to 50 μm HMR-1098, a selective sarcKATPchannel blocker, or 100 μm 5-hydroxydecanoate, a selective mitoKATPchannel blocker, 5 min before exposure to volatile anesthetics (1 MAC sevoflurane or isoflurane for 15 min). Subsequent ischemia was maintained for 60 or 120 min. HMR-1098 did not diminish protection elicited by volatile anesthetics (after 120 min of ischemia, sevoflurane: 45 ± 4%vs  . sevoflurane + HMR-1098: 44 ± 3%; isoflurane: 39 ± 3%vs  . isoflurane + HMR-1098: 41 ± 4%; not significant, n = 8). In contrast, 5-hydroxydecanoate completely abolished this protection, as assessed by hypoosmolar trypan blue staining (after 120 min of ischemia, sevoflurane: 45 ± 4%vs  . sevoflurane + 5-hydroxydecanoate: 63 ± 4%; isoflurane: 39 ± 3%vs  . isoflurane + 5-hydroxydecanoate: 61 ± 3%;P  < 0.0001, n = 8, sevoflurane + 5-hydroxydecanoate and isoflurane + 5-hydroxydecanoate vs  . control (ischemia alone); not significant, n = 8) (fig. 2). These experiments clearly indicate at a cellular level that mitoKATPchannels play a pivotal role in ischemic protection elicited by volatile anesthetics.
Fig. 2. Effects of the specific mitochondrial KATP(mitoKATP) channel blocker 5-hydroxydecanoate (5HD) and the specific sarcolemmal KATP(sarcKATP) channel blocker HMR-1098 on sevoflurane (SEVO)- and isoflurane (ISO)-mediated protection at 1 MAC against 60 or 120 min of ischemia in myocytes as assessed by trypan blue staining. (A  ) Control myocytes after 60 min of ischemia. Myocytes staining dark blue indicate irreversible cell damage. (B  ) Myocytes exposed to SEVO before ischemia. Most myocytes retain their rod-shaped morphology. (C  ) Myocytes exposed to 5HD and SEVO before ischemia. The protective effect of SEVO is abolished. (D  ) Myocytes exposed to HMR-1098 and SEVO before ischemia. The protection by SEVO is unaffected. (E  ) Representative trypan blue–positive and –negative myocytes after exposure to ischemia seen at higher magnification. (F  ) Trypan blue–positive myocytes are indicated as percentage of total viable myocytes before ischemia. CTL indicates control group and represents myocytes exposed to 60 or 120 min of ischemia alone. Data are mean ± SD. *P  < 0.0001 versus  respective CTL. #P  not significant versus  respective CTL.
Fig. 2. Effects of the specific mitochondrial KATP(mitoKATP) channel blocker 5-hydroxydecanoate (5HD) and the specific sarcolemmal KATP(sarcKATP) channel blocker HMR-1098 on sevoflurane (SEVO)- and isoflurane (ISO)-mediated protection at 1 MAC against 60 or 120 min of ischemia in myocytes as assessed by trypan blue staining. (A 
	) Control myocytes after 60 min of ischemia. Myocytes staining dark blue indicate irreversible cell damage. (B 
	) Myocytes exposed to SEVO before ischemia. Most myocytes retain their rod-shaped morphology. (C 
	) Myocytes exposed to 5HD and SEVO before ischemia. The protective effect of SEVO is abolished. (D 
	) Myocytes exposed to HMR-1098 and SEVO before ischemia. The protection by SEVO is unaffected. (E 
	) Representative trypan blue–positive and –negative myocytes after exposure to ischemia seen at higher magnification. (F 
	) Trypan blue–positive myocytes are indicated as percentage of total viable myocytes before ischemia. CTL indicates control group and represents myocytes exposed to 60 or 120 min of ischemia alone. Data are mean ± SD. *P 
	< 0.0001 versus 
	respective CTL. #P 
	not significant versus 
	respective CTL.
Fig. 2. Effects of the specific mitochondrial KATP(mitoKATP) channel blocker 5-hydroxydecanoate (5HD) and the specific sarcolemmal KATP(sarcKATP) channel blocker HMR-1098 on sevoflurane (SEVO)- and isoflurane (ISO)-mediated protection at 1 MAC against 60 or 120 min of ischemia in myocytes as assessed by trypan blue staining. (A  ) Control myocytes after 60 min of ischemia. Myocytes staining dark blue indicate irreversible cell damage. (B  ) Myocytes exposed to SEVO before ischemia. Most myocytes retain their rod-shaped morphology. (C  ) Myocytes exposed to 5HD and SEVO before ischemia. The protective effect of SEVO is abolished. (D  ) Myocytes exposed to HMR-1098 and SEVO before ischemia. The protection by SEVO is unaffected. (E  ) Representative trypan blue–positive and –negative myocytes after exposure to ischemia seen at higher magnification. (F  ) Trypan blue–positive myocytes are indicated as percentage of total viable myocytes before ischemia. CTL indicates control group and represents myocytes exposed to 60 or 120 min of ischemia alone. Data are mean ± SD. *P  < 0.0001 versus  respective CTL. #P  not significant versus  respective CTL.
×
Volatile Anesthetics Potentiate Diazoxide-mediated Myocyte Protection
Diazoxide is known as a highly selective potent opener of the mitoKATPchannels (2,000-fold more potent at the mitochondrial channel than at the surface channel). To test whether volatile anesthetics further potentiate the opening effect of diazoxide on mitoKATPchannels, myocytes where exposed to increasing concentrations of diazoxide (1 μm, 10 μm, 100 μm) in the presence of sevoflurane or isoflurane (1 MAC for 15 min) before 60 or 120 min of ischemia. Volatile anesthetics markedly potentiated the protective effect of diazoxide and significantly reduced the percentage of trypan blue–positive myocytes (100 μm diazoxide: 22 ± 3%vs  . 100 μm diazoxide + 1 MAC sevoflurane: 11 ± 2% and 100 μm diazoxide + 1 MAC isoflurane: 10 ± 2%, P  < 0.0001, n = 8), with isoflurane slightly more potent than sevoflurane at the diazoxide concentrations of 1 μm and 10 μm (fig. 3). The results of these experiments suggest that volatile anesthetics enhance opening of mitoKATPchannels.
Fig. 3. Potentiation of diazoxide (DIAZO)-induced protection (0, 1, 10, and 100 μm) by sevoflurane (SEVO) and isoflurane (ISO) at 1 MAC in myocytes exposed to 120 min of simulated ischemia as assessed by hypoosmolar trypan blue staining. Trypan blue–positive myocytes are indicated as percentage of total viable myocytes before ischemia. Data are mean ± SD. *P  < 0.0001 versus  respective treatment without SEVO or ISO. #P  < 0.001, SEVO versus  ISO. †P  not significant, SEVO versus  ISO.
Fig. 3. Potentiation of diazoxide (DIAZO)-induced protection (0, 1, 10, and 100 μm) by sevoflurane (SEVO) and isoflurane (ISO) at 1 MAC in myocytes exposed to 120 min of simulated ischemia as assessed by hypoosmolar trypan blue staining. Trypan blue–positive myocytes are indicated as percentage of total viable myocytes before ischemia. Data are mean ± SD. *P 
	< 0.0001 versus 
	respective treatment without SEVO or ISO. #P 
	< 0.001, SEVO versus 
	ISO. †P 
	not significant, SEVO versus 
	ISO.
Fig. 3. Potentiation of diazoxide (DIAZO)-induced protection (0, 1, 10, and 100 μm) by sevoflurane (SEVO) and isoflurane (ISO) at 1 MAC in myocytes exposed to 120 min of simulated ischemia as assessed by hypoosmolar trypan blue staining. Trypan blue–positive myocytes are indicated as percentage of total viable myocytes before ischemia. Data are mean ± SD. *P  < 0.0001 versus  respective treatment without SEVO or ISO. #P  < 0.001, SEVO versus  ISO. †P  not significant, SEVO versus  ISO.
×
Volatile Anesthetics Prime Activation of MitoKATPChannels as assessed by Flavoprotein Oxidation–Enhanced Autofluorescence in Myocytes
The redox state of flavoproteins directly reflects mitoKATPchannel activity. To test whether volatile anesthetics directly open mitoKATPchannels, the effect of sevoflurane and isoflurane on flavoprotein oxidation was visualized using fluorescence microscopy. Notably, exposure of sevoflurane and isoflurane as long as 30 min did not alter flavoprotein oxidation as compared with baseline values. Conversely, diazoxide administration to myocytes pretreated with sevoflurane (2.8%[vol/vol]) and isoflurane (1.2%[vol/vol]) clearly accelerated as well as markedly enhanced diazoxide-induced increases in flavoprotein-mediated autofluorescence, which indicates that volatile anesthetics prime activation of mitoKATPbut do not open the channel directly (fig. 4). Importantly, coadministration of chelerythrine (2 μm), a specific protein kinase C (PKC) inhibitor, to sevoflurane abolished the priming effect of sevoflurane on diazoxide. Similar results were obtained for isoflurane.
Fig. 4. Effect of sevoflurane (SEVO) (2.8%[vol/vol]) on diazoxide (DIAZO)-induced flavoprotein oxidation in myocytes excited at 480 nm. Similar results were obtained for isoflurane. An artificial color scale was used to visualize the relative intensity of emitted fluorescence at 530 nm (dark blue indicates reduced flavoproteins; red indicates fully oxidized flavoproteins). (A  ) At baseline. (B  ) At 100 μm DIAZO (same cells). (C  ) At 2 MAC SEVO. (D  ) At 100 μm DIAZO preceded by 2 MAC SEVO. Red color indicates intense local oxidation by mitochondrial clusters. (E  ) At 100 μm 2,4-dinitrophenol (DNP). (F  ) Mean percentages of peak flavoprotein fluorescence depending on the drugs exposed to myocytes. *P  < 0.0001 versus  baseline or SEVO + DIAZO versus  DIAZO alone. #P  not significantly different from DIAZO. †P  not significantly different from baseline. SEVO/CHE indicates concomitant treatment of myocytes with SEVO and chelerythrine (CHE) at 2 μm before exposure to DIAZO. (G  ) Time-lapse analysis of alterations in fluorescence intensity in individual myocytes expressed as percentage of DNP-induced fluorescence (see text). The blue squares and red circles indicate values from 8 different experiments. (H  ) Latency to peak activation of mitoKATPchannels in response to the various treatment regimens. *P  < 0.001 versus  DIAZO. #P  not significant versus  DIAZO. Data are mean ± SD.
Fig. 4. Effect of sevoflurane (SEVO) (2.8%[vol/vol]) on diazoxide (DIAZO)-induced flavoprotein oxidation in myocytes excited at 480 nm. Similar results were obtained for isoflurane. An artificial color scale was used to visualize the relative intensity of emitted fluorescence at 530 nm (dark blue indicates reduced flavoproteins; red indicates fully oxidized flavoproteins). (A 
	) At baseline. (B 
	) At 100 μm DIAZO (same cells). (C 
	) At 2 MAC SEVO. (D 
	) At 100 μm DIAZO preceded by 2 MAC SEVO. Red color indicates intense local oxidation by mitochondrial clusters. (E 
	) At 100 μm 2,4-dinitrophenol (DNP). (F 
	) Mean percentages of peak flavoprotein fluorescence depending on the drugs exposed to myocytes. *P 
	< 0.0001 versus 
	baseline or SEVO + DIAZO versus 
	DIAZO alone. #P 
	not significantly different from DIAZO. †P 
	not significantly different from baseline. SEVO/CHE indicates concomitant treatment of myocytes with SEVO and chelerythrine (CHE) at 2 μm before exposure to DIAZO. (G 
	) Time-lapse analysis of alterations in fluorescence intensity in individual myocytes expressed as percentage of DNP-induced fluorescence (see text). The blue squares and red circles indicate values from 8 different experiments. (H 
	) Latency to peak activation of mitoKATPchannels in response to the various treatment regimens. *P 
	< 0.001 versus 
	DIAZO. #P 
	not significant versus 
	DIAZO. Data are mean ± SD.
Fig. 4. Effect of sevoflurane (SEVO) (2.8%[vol/vol]) on diazoxide (DIAZO)-induced flavoprotein oxidation in myocytes excited at 480 nm. Similar results were obtained for isoflurane. An artificial color scale was used to visualize the relative intensity of emitted fluorescence at 530 nm (dark blue indicates reduced flavoproteins; red indicates fully oxidized flavoproteins). (A  ) At baseline. (B  ) At 100 μm DIAZO (same cells). (C  ) At 2 MAC SEVO. (D  ) At 100 μm DIAZO preceded by 2 MAC SEVO. Red color indicates intense local oxidation by mitochondrial clusters. (E  ) At 100 μm 2,4-dinitrophenol (DNP). (F  ) Mean percentages of peak flavoprotein fluorescence depending on the drugs exposed to myocytes. *P  < 0.0001 versus  baseline or SEVO + DIAZO versus  DIAZO alone. #P  not significantly different from DIAZO. †P  not significantly different from baseline. SEVO/CHE indicates concomitant treatment of myocytes with SEVO and chelerythrine (CHE) at 2 μm before exposure to DIAZO. (G  ) Time-lapse analysis of alterations in fluorescence intensity in individual myocytes expressed as percentage of DNP-induced fluorescence (see text). The blue squares and red circles indicate values from 8 different experiments. (H  ) Latency to peak activation of mitoKATPchannels in response to the various treatment regimens. *P  < 0.001 versus  DIAZO. #P  not significant versus  DIAZO. Data are mean ± SD.
×
Chelerythrine was previously reported to enhance fluorescence unspecifically. 17 However, at the low concentration of 2 μm used in the present work, chelerythrine did not affect baseline fluorescence of the flavoproteins (flavoprotein oxidation at emission wavelength of 530 nm of chelerythrine alone was 18 ± 3% as compared to control [16 ± 2%] in the absence of chelerythrine). We also tested whether chelerythrine alone would modify the subsequent diazoxide-induced fluorescence peak. Pretreatment with chelerythrine did not alter the diazoxide-induced fluorescence peak (41 ± 3%) compared to diazoxide without chelerythrine pretreatment (40 ± 4%).
Conversely, l-NAME, l-NIL, and PTIO could only be used in the experiments using the model of simulated ischemia on isolated myocytes. The latter three substances were found to significantly suppress baseline flavoprotein fluorescence: flavoprotein oxidation was 4 ± 2% for 100 μm PTIO, 7 ± 2% for 50 μm l-NAME, and 7 ± 3% for 50 μm l-NIL compared to baseline (16 ± 2%).
Myocyte Protection by Volatile Anesthetics is Mediated by Adenosine-Gi– and Nitric Oxide–sensitive Signaling Pathways and Involves Activation of Protein Kinase C
A number of modulators known to be involved in ischemic preconditioning were used to test their effects on volatile anesthetic–induced cellular protection. At the same time, this allowed us to define the main signaling pathways, which are known to contribute to the preconditioned state. Isolated myocytes were exposed to 2 MAC sevoflurane since the dose–response with regard to cellular protection leveled off between 1.5 and 2 MAC (fig. 1). The concentrations of the modulators used in these experiments were established in separate experiments and represent the concentrations required to obtain the maximum inhibitory or stimulatory effects on the signaling components under investigation. The percentage of trypan blue–positive myocytes as a measure for cell viability was evaluated after 120 min of ischemia. Concentration dependence of individual modulators and controls are summarized in table 1. The data concerning the specific effects of individual modulators at maximum inhibitory or stimulatory effects from table 1is visualized for comparison in figure 5.
Table 1. Percent Trypan Blue Positive Myocytes at Increasing Concentrations of Modulators after Exposure to 120 min of Ischemia
Image not available
Table 1. Percent Trypan Blue Positive Myocytes at Increasing Concentrations of Modulators after Exposure to 120 min of Ischemia
×
Fig. 5. Effects of specific modulators on sevoflurane (SEVO)-mediated protection in myocytes exposed to 120 min of ischemia followed by hypoosmolar trypan blue. Trypan blue–positive myocytes are indicated as percentage of total viable myocytes before ischemia. CTL indicates control group and represents myocytes exposed to 120 min of ischemia alone. Data are mean ± SD. *P  < 0.001 versus  CTL. #P  not significant versus  CTL. †P  not significant versus  SEVO at 2 MAC. Abbreviations and concentrations of drugs used: 100 μm 8-sulfophenyl theophylline (STP), 100 μm 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), 100 μm adenosine (ADO), 0.1 μm prazosin (PRZ), 5 μm propranolol (PRO), 2 μm chelerythrine (CHE), 100 μm 5-hydroxydecanoate (5HD), 50 μm HMR-1098, 100 μm 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazole-1-oxyl-3-oxide (PTIO), 1 μg/ml pertussis toxin (PTX), 50 μm l-NAME, 50 μm l-NIL, 1 mm 8-bromo-cGMP (8Br-cGMP), and 100 μm S  -nitroso-N  -acetyl-dl-penicillamine (SNAP).
Fig. 5. Effects of specific modulators on sevoflurane (SEVO)-mediated protection in myocytes exposed to 120 min of ischemia followed by hypoosmolar trypan blue. Trypan blue–positive myocytes are indicated as percentage of total viable myocytes before ischemia. CTL indicates control group and represents myocytes exposed to 120 min of ischemia alone. Data are mean ± SD. *P 
	< 0.001 versus 
	CTL. #P 
	not significant versus 
	CTL. †P 
	not significant versus 
	SEVO at 2 MAC. Abbreviations and concentrations of drugs used: 100 μm 8-sulfophenyl theophylline (STP), 100 μm 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), 100 μm adenosine (ADO), 0.1 μm prazosin (PRZ), 5 μm propranolol (PRO), 2 μm chelerythrine (CHE), 100 μm 5-hydroxydecanoate (5HD), 50 μm HMR-1098, 100 μm 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazole-1-oxyl-3-oxide (PTIO), 1 μg/ml pertussis toxin (PTX), 50 μm l-NAME, 50 μm l-NIL, 1 mm 8-bromo-cGMP (8Br-cGMP), and 100 μm S 
	-nitroso-N 
	-acetyl-dl-penicillamine (SNAP).
Fig. 5. Effects of specific modulators on sevoflurane (SEVO)-mediated protection in myocytes exposed to 120 min of ischemia followed by hypoosmolar trypan blue. Trypan blue–positive myocytes are indicated as percentage of total viable myocytes before ischemia. CTL indicates control group and represents myocytes exposed to 120 min of ischemia alone. Data are mean ± SD. *P  < 0.001 versus  CTL. #P  not significant versus  CTL. †P  not significant versus  SEVO at 2 MAC. Abbreviations and concentrations of drugs used: 100 μm 8-sulfophenyl theophylline (STP), 100 μm 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), 100 μm adenosine (ADO), 0.1 μm prazosin (PRZ), 5 μm propranolol (PRO), 2 μm chelerythrine (CHE), 100 μm 5-hydroxydecanoate (5HD), 50 μm HMR-1098, 100 μm 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazole-1-oxyl-3-oxide (PTIO), 1 μg/ml pertussis toxin (PTX), 50 μm l-NAME, 50 μm l-NIL, 1 mm 8-bromo-cGMP (8Br-cGMP), and 100 μm S  -nitroso-N  -acetyl-dl-penicillamine (SNAP).
×
The unselective adenosine receptor blocker SPT and the selective adenosine 1 receptor blocker DPCPX significantly attenuated the sevoflurane-induced protection but did not completely block its protective effect (fig. 5). Furthermore, the Gi-inhibiting PTX significantly decreased protection by sevoflurane, and adenosine at 100 μm elicited significant protection, which was, however, less pronounced than administration of 2 MAC sevoflurane (2 MAC sevoflurane: 30 ± 3%vs  . adenosine 42 ± 4%, P  < 0.001, n = 8). Notably, SPT, DPCPX, and PTX alone did not affect the percentage of trypan blue–positive myocytes exposed to 120 min of ischemia. Taken together, these results indicate that mechanisms other than pure stimulation of adenosine receptors contribute to the protection elicited by volatile anesthetics in rat ventricular myocytes.
To determine the role of nitric oxide (NO) in mediating sevoflurane-induced ischemic protection, myocytes were treated with the NO-scavenger PTIO (100 μm) and the NO synthase (NOS) inhibitors l-NAME (50 μm) and l-NIL (50 μm) (relatively specific for inducible NOS). PTIO and both NOS inhibitors significantly diminished but did not abolish the protective effect of sevoflurane. PTIO, l-NAME, and l-NIL alone did not affect the percentage of trypan blue–positive myocytes exposed to 120 min of ischemia. In accordance with this observation, SNAP at 100 μm, a NO donor, and 8-bromo-cGMP at 1 mm, a membrane-permeable analog of cGMP, which is an important mediator of many NO effects, prevented myocytes from undergoing irreversible ischemic damage. Notably, prazosin at 0.1 μm and propranolol at 5 μm did not affect sevoflurane-induced protection. The PKC inhibitor chelerythrine at 2 μm alone and the coadministration of 100 μm SPT and 100 μm PTIO completely abolished the cytoprotection by sevoflurane. Chelerythrine, prazosin, and propranolol alone did not affect the percentage of trypan blue–positive myocytes exposed to 120 min of ischemia.
The results of these experiments suggest that, in rat ventricular myocytes, multiple signaling pathways may contribute to sevoflurane-induced protection against ischemia, which presumably culminate in activation of PKC and thereby prime mitoKATPchannels. Figure 6depicts a simplified scheme of the signaling circuits hypothetically involved in the priming of the mitoKATPchannel in response to volatile anesthetics.
Fig. 6. Simplified scheme of signaling circuits potentially involved in the priming effect of volatile anesthetics on the mitochondrial KATP(mitoKATP) channel. Surface receptors may variably couple to different classes of G-protein subunits (Gαs, Gαi, Gαq, Gβγ). The main routes of activation by volatile anesthetics involve the Gαi protein–coupled adenosine receptor and the production of nitric oxide (NO), probably by modulation of NO synthase (NOS) activity. These two signaling pathways converge at the level of the protein kinase C (PKC), although alternative routes for NO could be operative as well. Lines with blunted ends (=) indicate inhibitors used in the present work. 8-bromo-cGMP (8Br-cGMP) partially mimics the effect of volatile anesthetics possibly by activation of the mitoKATPchannel via  protein kinase G (PKG) (dashed arrow). Inhibition of Gαi by pertussis toxin (PTX), inhibition of NOS by l-NIL and l-NAME, or scavenging of NO by PTIO, all partially reduce the myocyte protection of volatile anesthetics. The adrenergic receptor blockers prazosin (PRZ) and propranolol (PRO) do not affect the protection by isoflurane and sevoflurane.
Fig. 6. Simplified scheme of signaling circuits potentially involved in the priming effect of volatile anesthetics on the mitochondrial KATP(mitoKATP) channel. Surface receptors may variably couple to different classes of G-protein subunits (Gαs, Gαi, Gαq, Gβγ). The main routes of activation by volatile anesthetics involve the Gαi protein–coupled adenosine receptor and the production of nitric oxide (NO), probably by modulation of NO synthase (NOS) activity. These two signaling pathways converge at the level of the protein kinase C (PKC), although alternative routes for NO could be operative as well. Lines with blunted ends (=) indicate inhibitors used in the present work. 8-bromo-cGMP (8Br-cGMP) partially mimics the effect of volatile anesthetics possibly by activation of the mitoKATPchannel via 
	protein kinase G (PKG) (dashed arrow). Inhibition of Gαi by pertussis toxin (PTX), inhibition of NOS by l-NIL and l-NAME, or scavenging of NO by PTIO, all partially reduce the myocyte protection of volatile anesthetics. The adrenergic receptor blockers prazosin (PRZ) and propranolol (PRO) do not affect the protection by isoflurane and sevoflurane.
Fig. 6. Simplified scheme of signaling circuits potentially involved in the priming effect of volatile anesthetics on the mitochondrial KATP(mitoKATP) channel. Surface receptors may variably couple to different classes of G-protein subunits (Gαs, Gαi, Gαq, Gβγ). The main routes of activation by volatile anesthetics involve the Gαi protein–coupled adenosine receptor and the production of nitric oxide (NO), probably by modulation of NO synthase (NOS) activity. These two signaling pathways converge at the level of the protein kinase C (PKC), although alternative routes for NO could be operative as well. Lines with blunted ends (=) indicate inhibitors used in the present work. 8-bromo-cGMP (8Br-cGMP) partially mimics the effect of volatile anesthetics possibly by activation of the mitoKATPchannel via  protein kinase G (PKG) (dashed arrow). Inhibition of Gαi by pertussis toxin (PTX), inhibition of NOS by l-NIL and l-NAME, or scavenging of NO by PTIO, all partially reduce the myocyte protection of volatile anesthetics. The adrenergic receptor blockers prazosin (PRZ) and propranolol (PRO) do not affect the protection by isoflurane and sevoflurane.
×
Discussion
The principal new findings of this investigation are as follows. Volatile anesthetics do not directly open mitoKATPchannels but prime mitoKATPchannel activity. First, volatile anesthetics did not affect basal flavoprotein fluorescence in myocytes but potentiated the oxidative effect of the highly specific mitoKATPchannel opener diazoxide. Their coadministration to diazoxide also abbreviated the latency to peak mitoKATPchannel activity. Second, diazoxide-induced myocyte protection was potentiated by volatile anesthetics in a cellular model of simulated ischemia. Opening of the mitoKATPchannels, but not sarcKATPchannels, elicited this protection. The specific PKC inhibitor chelerythrine completely abrogated both the enhanced flavoprotein oxidation and the cellular protection induced by volatile anesthetics. This suggests that PKC represents a key signaling component upstream of the mitoKATPchannel and that these two events are closely associated. Lastly, our experiments indicate that the cardioprotective potency of volatile anesthetics parallels MAC values, but that different volatile anesthetics may confer varying degrees of protection at equipotent MAC values.
Recent studies focused on the elucidation of the molecular mechanisms that are involved in anesthetic-induced preconditioning. Since simultaneous administration of ischemic preconditioning and volatile anesthetics does not induce additional protection over that provided by each intervention alone, cardioprotection by volatile anesthetics is thought to be mediated by the same end effector as classic preconditioning. 21 Using blockers of the KATPchannel, many studies identified this channel in a multitude of animal models and experimental conditions as a key element in mediating the anesthetic-induced preconditioned state. 2,3,9,22,23 Most recently, effective preconditioning of human atrial trabeculae by isoflurane, but not halothane, was reported, and this effect was clearly abolished by glibenclamide, a nonspecific KATPchannel blocker. 24 Furthermore, desflurane reduced myocardial infarction size through mitoKATPchannels as well as sarcKATPchannels, 9 and sevoflurane was found to protect stunned myocardium, 25 which was blocked by the specific mitoKATPchannel blocker 5-hydroxydecanoate. Although recent data suggest that the mitoKATPchannel is even more important in mediating preconditioning-like effects, so far, no data were available with respect to interactions between volatile anesthetics and mitoKATPchannel activity. Only one study investigated the effects of isoflurane on sarcKATPchannel activity in rabbit ventricular myocytes and revealed that isoflurane inhibits channel activity without a change in single channel conductance. 10 However, isoflurane decreased the ATP sensitivity of the channel, leading to increased probability of channel opening for a given concentration of ATP. The results of our study are in line with these observations in sarcKATPchannels in so much as no direct opening of the mitoKATPchannel is recorded in response to volatile anesthetics.
The use of autofluorescence emerged as a new tool with great impact in the endeavor to understand cellular mechanisms. 26 In mammalian cells, autofluorescence is caused largely by the reduced pyridine nucleotides [NAD(P)/H] and by the oxidized flavoproteins (FAD/H2). These endogenous fluorophores transfer electrons to oxygen in the inner mitochondrial membrane, ultimately leading to formation of H2O and synthesis of ATP. The excitation of flavoproteins (excitation maximum at 480 nm) is maximal under full oxidation and minimal under full reduction, whereas the opposite is true for NAD(P)H (excitation maxima at 290, 336, 351 nm). The ratio of the concentration of oxidized and reduced electron carriers or of their fluorescence, respectively, therefore gives a measure of the cellular metabolic state. On the other hand, selective monitoring of flavoprotein-induced autofluorescence directly reflects mitoKATPchannel activity, as previously shown. 27 This noninvasive technique has been successfully used by Marbán et al  . to uncover important molecular mechanisms underlying the phenomenon of preconditioning. 14,16,17 A previous study investigated the effect of halothane (0.27 mm) on pyridine nucleotide [NAD(P)H]-induced autofluorescence in nonbeating rat ventricular myocytes. 28 Due to the opposite behavior of flavoprotein and pyridine nucleotides with respect to the redox state-dependent generation of autofluorescence, the results of this study could give some indications on how flavoproteins and thereby mitoKATPchannel activity could be affected by volatile anesthetics. Interestingly, no change in NAD(P)H-mediated autofluorescence was recorded in response to halothane in the absence of electrical stimulation, which indirectly implies that halothane, at the indicated concentration, did not affect basal flavoprotein-induced fluorescence or the mitoKATPchannel activity, respectively. This is in clear accordance with the results of our study.
How does activation of KATPchannels mediate cardioprotection? A cardioplegic-like effect with action potential shortening, decreased energy consumption, and reduced cytosolic Ca2+overload has been proposed as the protective mechanism caused by increased sarcKATPchannel activity. 6 Conversely, dissipation of the inner mitochondrial membrane potential in response to opening of the mitoKATPchannels blunts Ca2+overload of mitochondria 29 and leads to restoration of the mitochondrial intermembrane space, 30 which reestablishes functional coupling between adenine nucleotide translocase and creatine kinase as well as energy processes from mitochondria to ATP-utilizing cytosolic sites. 31 Interestingly, considerable cross-talk was documented between sarcKATPand mitoKATPchannels, whereby increased ATP consumption through uncoupled mitochondria leads, in turn, to activation of sarcKATPchannels. 32 The results of the current study emphasize the importance of the protective effects of mitoKATPchannel in mediating volatile anesthetic–induced protection, but the role of the sarcKATPchannel should not be totally dismissed.
Recently, Sato et al  . proposed a 3-state model, including resting, primed, and open state of the mitoKATPchannel. 17 This was motivated by the observation that adenosine did not affect basal mitoKATPchannel activity but significantly enhanced opening by diazoxide, a direct mitoKATPchannel opener. The primed receptor state allows easy and rapid opening at the initiation of ischemia, and most probably represents a specifically phosphorylated state of the receptor. In our study, isoflurane and sevoflurane similarly potentiated diazoxide-mediated effects, which were blocked by chelerythrine, a specific PKC inhibitor. The important role of adenosine receptors and PKC in the cardioprotection elicited by volatile anesthetics was repeatedly reported in previous studies. 24,33,34 Of note, volatile anesthetics may even directly activate PKC, although their reported actions on PKC are contradictory. The so-far hypothetical model of a primed receptor state could explain the recently observed decrease in time threshold by sevoflurane for ischemic preconditioning. 35 In this context, an antiprimed state of the mitoKATPchannel may also underlie the observed phenomenon of “antipreconditioning,” where the inability of the channel to open at initiation of ischemia may lead to the reported potentiated ischemic damage. 36 Taken together, priming of the mitoKATPchannel may reflect a general characteristic of this channel.
Using a cellular model of simulated ischemia, we evaluated the effects of specific blockers on various putative signaling pathways involved in the preconditioning-like state induced by volatile anesthetics. This in vitro  model mimics tissue ischemia by restriction of oxygen and extracellular fluid as well as accumulation of metabolites. 18,19 Subsequent superposition of an artificially high hypotonic stress upon cardiomyocytes allows sensitive detection of even latent ultrastructural ischemic lesions in sarcolemmal membrane integrity by trypan blue permeability exclusion. 20 The results of these experiments allowed us to delineate the signaling pathways involved in the preconditioned state in response to volatile anesthetics (fig. 6). Specifically, the involvement of G-protein–linked signaling, as previously shown in a canine model, 37 could be confirmed in our experiments. Two observations, however, need further consideration. First, although initially it was felt that adenosine receptors were not involved in preconditioning in rat, more recent evidence reveals that adenosine antagonists can at least blunt the preconditioning-induced protection. This is consistent with the results of our study, where two adenosine receptor antagonists, SPT and DPCPX, diminished the protective effects of volatile anesthetics. Also, a recent study in rat ventricular myocytes demonstrated that activation of adenosine 1 receptors reduces reactive oxygen species and significantly attenuates myocardial stunning. 38 Second, the presented results also suggest NO–cGMP as elements in volatile anesthetic–induced protection (fig. 6). Administration of the NO scavenger PTIO or the NOS inhibitors l-NAME and l-NIL clearly inhibited protection afforded by volatile anesthetics. Notably, NO and its metabolite peroxinitrite are known to activate PKC and the KATPchannels. 16 NO–cGMP signaling and basal NOS activity were previously reported to play an important role in pacing-associated preconditioning in the isolated rat heart. 39,40 Moreover, a recent study in chicken myocytes demonstrated the abrogation of preconditioning protection using 5-hydroxydecanoate or l-NAME. 41 It may well be that volatile anesthetics differentially modulate the activity of the various isoenzymes of NOS (nNOS, eNOS, iNOS), which are ubiquitous but heterogeneously distributed in myocytes. 42 Although the role of NO in late preconditioning (second window of protection) is well established, its role in early preconditioning, specifically in anesthetic-induced preconditioning, needs further investigations.
Apoptosis, the programmed cell death, plays a key role in myocardial infarction and the various forms of cardiomyopathies. Volatile anesthetics were recently reported to inhibit catecholamine-induced apoptosis in rat ventricular myocytes by modulation of cellular Ca2+homeostasis and inhibition of the apoptosis initiator caspase-9, which is closely related to mitochondrial integrity. 11 A recent study now links opening of the mitoKATPchannel to significant antiapoptotic effects in myocytes, 43 thereby raising the interesting possibility that cardioprotection by volatile anesthetics during ischemia may be caused by their priming effect on mitoKATPchannels. Taken together, the preconditioning effects of volatile anesthetics are sensitive to adenosine receptor– and NO-coupled signaling.
The results of the present study should be interpreted with caution. Specifically, we recognize that mechanistic information on preconditioning in rat myocytes may not be transferable to other species, in particular to humans. Also, isolated myocyte models have limitations with respect to the choice of external solutions, substrate selection, and unphysiologically low workload. In addition, the effects of only a limited number of putative signaling pathways involved in anesthetic-induced preconditioning were assessed in the present study. Importantly, the use of basal anesthesia, in particular the use of barbiturates 12 and ketamine, 13 has a great potential to affect experimental results and was therefore carefully avoided in our experiments. Even α-chloralose, which is appreciated for its neglectable effects on experimental results, can potentially affect KATPchannel activity by its main metabolite trichloroethanol, since ethanol is known to induce preconditioning. 44 Finally, although the question of whether sarcKATPor mitoKATPchannels would be the more important contributors to anesthetic-induced preconditioning in vivo  could not be clarified by our experimental model, the results of these studies pinpoint the mitoKATPchannel as a potential therapeutic target for cardioprotection.
In summary, volatile anesthetics prime mitoKATPchannels through multiple PKC-coupled signaling pathways in a model of isolated rat ventricular myocytes. Since anesthetic-induced preconditioning not only affects the heart but also may protect a variety of other tissues, 45 appropriate clinical studies are now needed to ascertain the utility and efficacy of this promising therapeutic strategy in perioperative medicine, specifically in patients at high risk for perioperative ischemic injury.
References
Murry CE, Jennings RB, Reimer KA: Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124–36Murry, CE Jennings, RB Reimer, KA
Warltier D, Al-Wathiqui M, Kampine J, Schmeling W: Recovery of contractile function of stunned myocardium in chronically instrumented dogs is enhanced by halothane or isoflurane. A nesthesiology 1989; 69: 552–65Warltier, D Al-Wathiqui, M Kampine, J Schmeling, W
Davis R, Sidi A: Effect of isoflurane on the extent of myocardial necrosis and on systemic hemodynamics, regional myocardial blood flow, and regional myocardial metabolism in dogs after coronary artery occlusion. Anesth Analg 1989; 69: 575–86Davis, R Sidi, A
Preckel B, Schlack W, Thämer V: Enflurane and isoflurane, but not halothane, protect against myocardial reperfusion injury after cardioplegic arrest with HTK solution in the isolated rat heart. Anesth Analg 1998; 87: 1221–7Preckel, B Schlack, W Thämer, V
Belhomme D, Peynet J, Louzy M, Launay JM, Kitakaze M, Menasché P: Evidence for preconditioning by isoflurane in coronary artery bypass graft surgery. Circulation 1999; 100(suppl II): II-340–4Belhomme, D Peynet, J Louzy, M Launay, JM Kitakaze, M Menasché, P
O'Rourke B: Myocardial KATPchannels in preconditioning. Circ Res 2000; 87: 845–55O'Rourke, B
Kersten JR, Gross GJ, Pagel PS, Warltier DC: Activation of adenosine triphosphate-regulated potassium channels. A nesthesiology 1998; 88: 495–513Kersten, JR Gross, GJ Pagel, PS Warltier, DC
Gross GJ, Fryer RM: Sarcolemmal versus mitochondrial ATP-sensitive K+channels and myocardial preconditioning. Circ Res 1999; 84: 973–79Gross, GJ Fryer, RM
Toller WG, Gross ER, Kersten JR, Pagel PS, Gross GJ, Warltier DC: Sarcolemmal and mitochondrial adenosine triphosphate-dependent potassium channels. A nesthesiology 2000; 92: 1731–9Toller, WG Gross, ER Kersten, JR Pagel, PS Gross, GJ Warltier, DC
Han J, Kim E, Ho WK, Earm YE: Effects of volatile anesthetic isoflurane on ATP-sensitive K+channels in rabbit ventricular myocardium. Biochem Biophys Res Commun 1996; 229: 852–6Han, J Kim, E Ho, WK Earm, YE
Zaugg M, Jamali NZ, Lucchinetti E, Shafiq SA, Siddiqui MAQ: Norepinephrine-induced apoptosis is inhibited in adult rat ventricular myocytes exposed to volatile anesthetics. A nesthesiology 2000; 93: 209–18Zaugg, M Jamali, NZ Lucchinetti, E Shafiq, SA Siddiqui, MAQ
Tsutsumi Y, Oshita S, Kitahata H, Kuroda Y, Kawano T, Nakaya Y: Blockade of adenosine triphosphate-sensitive potassium channels by thiamylal in rat ventricular myocytes. A nesthesiology 2000; 92: 1154–9Tsutsumi, Y Oshita, S Kitahata, H Kuroda, Y Kawano, T Nakaya, Y
Molojavyi A, Preckel B, Comfère T, Müllenheim J, Thämer V, Schlack W: Effects of ketamine and its isomers on ischemic preconditioning in the isolated rat heart. A nesthesiology 2001; 94: 623–9Molojavyi, A Preckel, B Comfère, T Müllenheim, J Thämer, V Schlack, W
Liu Y, Sato T, O'Rourke B, Marbán E: Mitochondrial ATP-dependent potassium channels: Novel effectors of cardioprotection? Circulation 1998; 97: 2463–9Liu, Y Sato, T O'Rourke, B Marbán, E
Romashko DN, Marbán E, O'Rourke B: Subcellular metabolic transients and mitochondrial redox waves in heart cells. Proc Natl Acad Sci U S A 1998; 95: 1618–23Romashko, DN Marbán, E O'Rourke, B
Sasaki N, Sato T, Ohler A, O'Rourke B, Marbán E: Activation of mitochondrial ATP-dependent potassium channels by nitric oxide. Circulation 2000; 101: 439–45Sasaki, N Sato, T Ohler, A O'Rourke, B Marbán, E
Sato T, Sasaki N, O'Rourke B, Marbán E: Adenosine primes the opening of mitochondrial ATP-sensitive potassium channels: A key step in ischemic preconditioning? Circulation 2000; 102: 800–5Sato, T Sasaki, N O'Rourke, B Marbán, E
Vander Heide RS, Rim D, Hohl CM, Ganote CE: An in vitro model of myocardial ischemia utilizing isolated adult rat myocytes. J Mol Cell Cardiol 1990; 22: 165–81Vander Heide, RS Rim, D Hohl, CM Ganote, CE
Armstrong SC, Hoover DB, Shivell LC, Ganote CE: Preconditioning of isolated rabbit cardiomyocytes: No evident separation of induction, memory and protection. J Mol Cell Cardiol 1997; 29: 2285–98Armstrong, SC Hoover, DB Shivell, LC Ganote, CE
Armstrong SC, Shivell LC, Ganote CE: Sarcolemmal blebs and osmotic fragility as correlates of irreversible ischemic injury in preconditioned isolated rabbit cardiomyocytes. J Mol Cell Cardiol 2001; 33: 149–60Armstrong, SC Shivell, LC Ganote, CE
Boutros A, Wang J, Capuano C: Isoflurane and halothane increase adenosine triphosphate preservation, but do not provide additive recovery of function after ischemia, in preconditioned rat hearts. A nesthesiology 1997; 86: 1009–17Boutros, A Wang, J Capuano, C
Kersten JR, Schmeling TJ, Hettrick DA, Pagel PS, Gross GJ, Warltier DC: Mechanism of myocardial protection by isoflurane. A nesthesiology 1996; 85: 794–807Kersten, JR Schmeling, TJ Hettrick, DA Pagel, PS Gross, GJ Warltier, DC
Cason BA, Gamperl AK, Slocum RE, Hickey RF: Anesthetic-induced preconditioning: Previous administration of isoflurane decreases myocardial infarct size in rabbits. A nesthesiology 1997; 87: 1182–90Cason, BA Gamperl, AK Slocum, RE Hickey, RF
Roscoe AK, Christensen JD, Lynch C: Isoflurane, but not halothane, induces protection of human myocardium via adenosine A1receptors and adenosine triphosphate-sensitive potassium channels. A nesthesiology 2001; 92: 1692–1701Roscoe, AK Christensen, JD Lynch, C
Hara T, Tomiyasu S, Sungsam C, Fukusaki M, Sumikawa K: Sevoflurane protects stunned myocardium through activation of mitochondrial ATP-sensitive potassium channels. Anesth Analg 2001; 92: 1139–45Hara, T Tomiyasu, S Sungsam, C Fukusaki, M Sumikawa, K
Harms GS, Cognet L, Lommerse PHM, Blab GA, Schmidt T: Autofluorescent proteins in single-molecule research: Applications to live cell imaging microscopy. Biophys J 2001; 80: 2396–408Harms, GS Cognet, L Lommerse, PHM Blab, GA Schmidt, T
Hajnoczky G, Robb-Gaspers LD, Seitz MB, Thomas AP: Decoding of cytosolic calcium oscillations in the mitochondria. Cell 1995; 82: 415–24Hajnoczky, G Robb-Gaspers, LD Seitz, MB Thomas, AP
Jiang Y, Julian FJ: Pacing rate, halothane, and BDM affect fura 2 reporting of [Ca2+]iin intact rat trabeculae. Am J Physiol 1997; 273: C2046–56Jiang, Y Julian, FJ
Liu Y, Sato T, Seharaseyon J, Szewczyk A, O'Rourke B, Marbán E: Mitochondrial ATP-dependent potassium channels: Viable candidate effectors of ischemic preconditioning. Ann NY Acad Sci 1999; 874: 27–37Liu, Y Sato, T Seharaseyon, J Szewczyk, A O'Rourke, B Marbán, E
Kowaltowski AJ, Seetharaman S, Paucek P, Garlid KD: Bioenergetic consequences of opening the ATP-sensitive K+channel of heart mitochondria. Am J Physiol 2001; 280: H649–57Kowaltowski, AJ Seetharaman, S Paucek, P Garlid, KD
Laclau MN, Boudina S, Thambo JB, Tariosse L, Gouverneur G, Bonoron-Adèle S, Saks VA, Garlid KD, Santos PD: Cardioprotection by ischemic preconditioning preserves mitochondrial function and functional coupling between adenine nucleotide translocase and creatine kinase. J Mol Cell Cardiol 2001; 33: 947–56Laclau, MN Boudina, S Thambo, JB Tariosse, L Gouverneur, G Bonoron-Adèle, S Saks, VA Garlid, KD Santos, PD
Sasaki N, Sato T, Marbán E, O'Rourke B: ATP consumption by uncoupled mitochondria activates sarcolemmal KATPchannels in cardiac myocytes. Am J Physiol 2001; 280: H1882–8Sasaki, N Sato, T Marbán, E O'Rourke, B
Toller WG, Montgomery MW, Pagel PS, Hettrick DA, Warltier DC, Kersten JR: Isoflurane-enhanced recovery of canine stunned myocardium. A nesthesiology 1999; 91: 713–22Toller, WG Montgomery, MW Pagel, PS Hettrick, DA Warltier, DC Kersten, JR
Ismaeli M, Tkachenko I, Hickey R, Cason BA: Colchicine inhibits isoflurane-induced myocardial preconditioning. A nesthesiology 1999; 90: 812–21Ismaeli, M Tkachenko, I Hickey, R Cason, BA
Toller WG, Kersten JR, Pagel PS, Hettrick DA, Warltier DC: Sevoflurane reduces myocardial infarction size and decreases the time threshold for ischemic preconditioning in dogs. A nesthesiology 1999; 91: 1437–46Toller, WG Kersten, JR Pagel, PS Hettrick, DA Warltier, DC
Aitchison KA, Baxter GF, Awan MM, Smith RM, Yellon DM, Opie LH: Opposing effects on infarction of delta and kappa opioid receptor activation in the isolated rat heart: Implications for ischemic preconditioning. Basic Res Cardiol 2000; 95: 1–10Aitchison, KA Baxter, GF Awan, MM Smith, RM Yellon, DM Opie, LH
Toller WG, Kersten JJR, Gross ER, Pagel PS, Warltier DC: Isoflurane preconditions myocardium against infarction via activation of inhibitory guanine nucleotide binding proteins. A nesthesiology 2000; 92: 1400–7Toller, WG Kersten, JJR Gross, ER Pagel, PS Warltier, DC
Narayan P, Mentzer RM, Lasley RD Jr: Adenosine A1receptor activation reduces reactive oxygen species and attenuates stunning in ventricular myocytes. J Mol Cell Biol 2001; 33: 121–9Narayan, P Mentzer, RM Lasley, RD
Ferdinandy P, Szilvássy Z, Balogh N, Csonka C, Csont T, Koltai M, Dux L: Nitric oxide is involved in active preconditioning in isolated working rat hearts. Ann NY Acad Sci 1996; 793: 489–93Ferdinandy, P Szilvássy, Z Balogh, N Csonka, C Csont, T Koltai, M Dux, L
Csonka C, Szilvássy Z, Fülöp F, Pali T, Blasig IE, Tosaki A, Schullz R, Ferdinandy P: Classic preconditioning decreases the harmful accumulation of nitric oxide during ischemia and reperfusion in rat hearts. Circulation 1999; 100: 2260–6Csonka, C Szilvássy, Z Fülöp, F Pali, T Blasig, IE Tosaki, A Schullz, R Ferdinandy, P
Hoek TL, Becker LB, Shao Z, Schumacker PT: Preconditioning antioxidant protection by KATPchannel opening requires nitric oxide synthase. Acad Emerg Med 2001; 8: 548–9Hoek, TL Becker, LB Shao, Z Schumacker, PT
Brahmajothi MV, Campbell DL: Heterogeneous basal expression of nitric oxide synthase and superoxide dismutase isoforms in mammalian heart: Implications for mechanisms governing indirect and direct nitric-oxide-related effects. Circulation 1999; 85: 575–87Brahmajothi, MV Campbell, DL
Akao M, Ohler A, O'Rourke B, Marbán E: Mitochondrial ATP-sensitive potassium channels inhibit apoptosis induced by oxidative stress in cardiac cells. Circ Res 2001; 88: 1267–75Akao, M Ohler, A O'Rourke, B Marbán, E
Chen C, Gray MO, Mochly-Rosen D: Cardioprotection from ischemia by a brief exposure to physiological levels of ethanol: Role of epsilon protein kinase C. Proc Natl Acad Sci U S A 1999; 96: 12784–9Chen, C Gray, MO Mochly-Rosen, D
Lynch C: Anesthetic preconditioning: Not just for the heart? A nesthesiology 1999; 91: 606–8Lynch, C
Fig. 1. Dose-dependent protection by sevoflurane (SEVO) and isoflurane (ISO) in myocytes exposed to 60 or 120 min of ischemia. The number of myocytes stained with trypan blue is indicated as percentage of total viable myocytes before ischemia. Data are mean ± SD. MAC = minimum alveolar concentration; CTL = control group. *P  < 0.001, any bar of SEVO- or ISO-treated myocytes versus  the respective CTL bar or the respec-tive bar at the preceding lower MAC value. #P  not significant, bar of SEVO- or ISO-treated myocytes at 2.0 MAC versus  the respective bar at 1.5 MAC.
Fig. 1. Dose-dependent protection by sevoflurane (SEVO) and isoflurane (ISO) in myocytes exposed to 60 or 120 min of ischemia. The number of myocytes stained with trypan blue is indicated as percentage of total viable myocytes before ischemia. Data are mean ± SD. MAC = minimum alveolar concentration; CTL = control group. *P 
	< 0.001, any bar of SEVO- or ISO-treated myocytes versus 
	the respective CTL bar or the respec-tive bar at the preceding lower MAC value. #P 
	not significant, bar of SEVO- or ISO-treated myocytes at 2.0 MAC versus 
	the respective bar at 1.5 MAC.
Fig. 1. Dose-dependent protection by sevoflurane (SEVO) and isoflurane (ISO) in myocytes exposed to 60 or 120 min of ischemia. The number of myocytes stained with trypan blue is indicated as percentage of total viable myocytes before ischemia. Data are mean ± SD. MAC = minimum alveolar concentration; CTL = control group. *P  < 0.001, any bar of SEVO- or ISO-treated myocytes versus  the respective CTL bar or the respec-tive bar at the preceding lower MAC value. #P  not significant, bar of SEVO- or ISO-treated myocytes at 2.0 MAC versus  the respective bar at 1.5 MAC.
×
Fig. 2. Effects of the specific mitochondrial KATP(mitoKATP) channel blocker 5-hydroxydecanoate (5HD) and the specific sarcolemmal KATP(sarcKATP) channel blocker HMR-1098 on sevoflurane (SEVO)- and isoflurane (ISO)-mediated protection at 1 MAC against 60 or 120 min of ischemia in myocytes as assessed by trypan blue staining. (A  ) Control myocytes after 60 min of ischemia. Myocytes staining dark blue indicate irreversible cell damage. (B  ) Myocytes exposed to SEVO before ischemia. Most myocytes retain their rod-shaped morphology. (C  ) Myocytes exposed to 5HD and SEVO before ischemia. The protective effect of SEVO is abolished. (D  ) Myocytes exposed to HMR-1098 and SEVO before ischemia. The protection by SEVO is unaffected. (E  ) Representative trypan blue–positive and –negative myocytes after exposure to ischemia seen at higher magnification. (F  ) Trypan blue–positive myocytes are indicated as percentage of total viable myocytes before ischemia. CTL indicates control group and represents myocytes exposed to 60 or 120 min of ischemia alone. Data are mean ± SD. *P  < 0.0001 versus  respective CTL. #P  not significant versus  respective CTL.
Fig. 2. Effects of the specific mitochondrial KATP(mitoKATP) channel blocker 5-hydroxydecanoate (5HD) and the specific sarcolemmal KATP(sarcKATP) channel blocker HMR-1098 on sevoflurane (SEVO)- and isoflurane (ISO)-mediated protection at 1 MAC against 60 or 120 min of ischemia in myocytes as assessed by trypan blue staining. (A 
	) Control myocytes after 60 min of ischemia. Myocytes staining dark blue indicate irreversible cell damage. (B 
	) Myocytes exposed to SEVO before ischemia. Most myocytes retain their rod-shaped morphology. (C 
	) Myocytes exposed to 5HD and SEVO before ischemia. The protective effect of SEVO is abolished. (D 
	) Myocytes exposed to HMR-1098 and SEVO before ischemia. The protection by SEVO is unaffected. (E 
	) Representative trypan blue–positive and –negative myocytes after exposure to ischemia seen at higher magnification. (F 
	) Trypan blue–positive myocytes are indicated as percentage of total viable myocytes before ischemia. CTL indicates control group and represents myocytes exposed to 60 or 120 min of ischemia alone. Data are mean ± SD. *P 
	< 0.0001 versus 
	respective CTL. #P 
	not significant versus 
	respective CTL.
Fig. 2. Effects of the specific mitochondrial KATP(mitoKATP) channel blocker 5-hydroxydecanoate (5HD) and the specific sarcolemmal KATP(sarcKATP) channel blocker HMR-1098 on sevoflurane (SEVO)- and isoflurane (ISO)-mediated protection at 1 MAC against 60 or 120 min of ischemia in myocytes as assessed by trypan blue staining. (A  ) Control myocytes after 60 min of ischemia. Myocytes staining dark blue indicate irreversible cell damage. (B  ) Myocytes exposed to SEVO before ischemia. Most myocytes retain their rod-shaped morphology. (C  ) Myocytes exposed to 5HD and SEVO before ischemia. The protective effect of SEVO is abolished. (D  ) Myocytes exposed to HMR-1098 and SEVO before ischemia. The protection by SEVO is unaffected. (E  ) Representative trypan blue–positive and –negative myocytes after exposure to ischemia seen at higher magnification. (F  ) Trypan blue–positive myocytes are indicated as percentage of total viable myocytes before ischemia. CTL indicates control group and represents myocytes exposed to 60 or 120 min of ischemia alone. Data are mean ± SD. *P  < 0.0001 versus  respective CTL. #P  not significant versus  respective CTL.
×
Fig. 3. Potentiation of diazoxide (DIAZO)-induced protection (0, 1, 10, and 100 μm) by sevoflurane (SEVO) and isoflurane (ISO) at 1 MAC in myocytes exposed to 120 min of simulated ischemia as assessed by hypoosmolar trypan blue staining. Trypan blue–positive myocytes are indicated as percentage of total viable myocytes before ischemia. Data are mean ± SD. *P  < 0.0001 versus  respective treatment without SEVO or ISO. #P  < 0.001, SEVO versus  ISO. †P  not significant, SEVO versus  ISO.
Fig. 3. Potentiation of diazoxide (DIAZO)-induced protection (0, 1, 10, and 100 μm) by sevoflurane (SEVO) and isoflurane (ISO) at 1 MAC in myocytes exposed to 120 min of simulated ischemia as assessed by hypoosmolar trypan blue staining. Trypan blue–positive myocytes are indicated as percentage of total viable myocytes before ischemia. Data are mean ± SD. *P 
	< 0.0001 versus 
	respective treatment without SEVO or ISO. #P 
	< 0.001, SEVO versus 
	ISO. †P 
	not significant, SEVO versus 
	ISO.
Fig. 3. Potentiation of diazoxide (DIAZO)-induced protection (0, 1, 10, and 100 μm) by sevoflurane (SEVO) and isoflurane (ISO) at 1 MAC in myocytes exposed to 120 min of simulated ischemia as assessed by hypoosmolar trypan blue staining. Trypan blue–positive myocytes are indicated as percentage of total viable myocytes before ischemia. Data are mean ± SD. *P  < 0.0001 versus  respective treatment without SEVO or ISO. #P  < 0.001, SEVO versus  ISO. †P  not significant, SEVO versus  ISO.
×
Fig. 4. Effect of sevoflurane (SEVO) (2.8%[vol/vol]) on diazoxide (DIAZO)-induced flavoprotein oxidation in myocytes excited at 480 nm. Similar results were obtained for isoflurane. An artificial color scale was used to visualize the relative intensity of emitted fluorescence at 530 nm (dark blue indicates reduced flavoproteins; red indicates fully oxidized flavoproteins). (A  ) At baseline. (B  ) At 100 μm DIAZO (same cells). (C  ) At 2 MAC SEVO. (D  ) At 100 μm DIAZO preceded by 2 MAC SEVO. Red color indicates intense local oxidation by mitochondrial clusters. (E  ) At 100 μm 2,4-dinitrophenol (DNP). (F  ) Mean percentages of peak flavoprotein fluorescence depending on the drugs exposed to myocytes. *P  < 0.0001 versus  baseline or SEVO + DIAZO versus  DIAZO alone. #P  not significantly different from DIAZO. †P  not significantly different from baseline. SEVO/CHE indicates concomitant treatment of myocytes with SEVO and chelerythrine (CHE) at 2 μm before exposure to DIAZO. (G  ) Time-lapse analysis of alterations in fluorescence intensity in individual myocytes expressed as percentage of DNP-induced fluorescence (see text). The blue squares and red circles indicate values from 8 different experiments. (H  ) Latency to peak activation of mitoKATPchannels in response to the various treatment regimens. *P  < 0.001 versus  DIAZO. #P  not significant versus  DIAZO. Data are mean ± SD.
Fig. 4. Effect of sevoflurane (SEVO) (2.8%[vol/vol]) on diazoxide (DIAZO)-induced flavoprotein oxidation in myocytes excited at 480 nm. Similar results were obtained for isoflurane. An artificial color scale was used to visualize the relative intensity of emitted fluorescence at 530 nm (dark blue indicates reduced flavoproteins; red indicates fully oxidized flavoproteins). (A 
	) At baseline. (B 
	) At 100 μm DIAZO (same cells). (C 
	) At 2 MAC SEVO. (D 
	) At 100 μm DIAZO preceded by 2 MAC SEVO. Red color indicates intense local oxidation by mitochondrial clusters. (E 
	) At 100 μm 2,4-dinitrophenol (DNP). (F 
	) Mean percentages of peak flavoprotein fluorescence depending on the drugs exposed to myocytes. *P 
	< 0.0001 versus 
	baseline or SEVO + DIAZO versus 
	DIAZO alone. #P 
	not significantly different from DIAZO. †P 
	not significantly different from baseline. SEVO/CHE indicates concomitant treatment of myocytes with SEVO and chelerythrine (CHE) at 2 μm before exposure to DIAZO. (G 
	) Time-lapse analysis of alterations in fluorescence intensity in individual myocytes expressed as percentage of DNP-induced fluorescence (see text). The blue squares and red circles indicate values from 8 different experiments. (H 
	) Latency to peak activation of mitoKATPchannels in response to the various treatment regimens. *P 
	< 0.001 versus 
	DIAZO. #P 
	not significant versus 
	DIAZO. Data are mean ± SD.
Fig. 4. Effect of sevoflurane (SEVO) (2.8%[vol/vol]) on diazoxide (DIAZO)-induced flavoprotein oxidation in myocytes excited at 480 nm. Similar results were obtained for isoflurane. An artificial color scale was used to visualize the relative intensity of emitted fluorescence at 530 nm (dark blue indicates reduced flavoproteins; red indicates fully oxidized flavoproteins). (A  ) At baseline. (B  ) At 100 μm DIAZO (same cells). (C  ) At 2 MAC SEVO. (D  ) At 100 μm DIAZO preceded by 2 MAC SEVO. Red color indicates intense local oxidation by mitochondrial clusters. (E  ) At 100 μm 2,4-dinitrophenol (DNP). (F  ) Mean percentages of peak flavoprotein fluorescence depending on the drugs exposed to myocytes. *P  < 0.0001 versus  baseline or SEVO + DIAZO versus  DIAZO alone. #P  not significantly different from DIAZO. †P  not significantly different from baseline. SEVO/CHE indicates concomitant treatment of myocytes with SEVO and chelerythrine (CHE) at 2 μm before exposure to DIAZO. (G  ) Time-lapse analysis of alterations in fluorescence intensity in individual myocytes expressed as percentage of DNP-induced fluorescence (see text). The blue squares and red circles indicate values from 8 different experiments. (H  ) Latency to peak activation of mitoKATPchannels in response to the various treatment regimens. *P  < 0.001 versus  DIAZO. #P  not significant versus  DIAZO. Data are mean ± SD.
×
Fig. 5. Effects of specific modulators on sevoflurane (SEVO)-mediated protection in myocytes exposed to 120 min of ischemia followed by hypoosmolar trypan blue. Trypan blue–positive myocytes are indicated as percentage of total viable myocytes before ischemia. CTL indicates control group and represents myocytes exposed to 120 min of ischemia alone. Data are mean ± SD. *P  < 0.001 versus  CTL. #P  not significant versus  CTL. †P  not significant versus  SEVO at 2 MAC. Abbreviations and concentrations of drugs used: 100 μm 8-sulfophenyl theophylline (STP), 100 μm 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), 100 μm adenosine (ADO), 0.1 μm prazosin (PRZ), 5 μm propranolol (PRO), 2 μm chelerythrine (CHE), 100 μm 5-hydroxydecanoate (5HD), 50 μm HMR-1098, 100 μm 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazole-1-oxyl-3-oxide (PTIO), 1 μg/ml pertussis toxin (PTX), 50 μm l-NAME, 50 μm l-NIL, 1 mm 8-bromo-cGMP (8Br-cGMP), and 100 μm S  -nitroso-N  -acetyl-dl-penicillamine (SNAP).
Fig. 5. Effects of specific modulators on sevoflurane (SEVO)-mediated protection in myocytes exposed to 120 min of ischemia followed by hypoosmolar trypan blue. Trypan blue–positive myocytes are indicated as percentage of total viable myocytes before ischemia. CTL indicates control group and represents myocytes exposed to 120 min of ischemia alone. Data are mean ± SD. *P 
	< 0.001 versus 
	CTL. #P 
	not significant versus 
	CTL. †P 
	not significant versus 
	SEVO at 2 MAC. Abbreviations and concentrations of drugs used: 100 μm 8-sulfophenyl theophylline (STP), 100 μm 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), 100 μm adenosine (ADO), 0.1 μm prazosin (PRZ), 5 μm propranolol (PRO), 2 μm chelerythrine (CHE), 100 μm 5-hydroxydecanoate (5HD), 50 μm HMR-1098, 100 μm 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazole-1-oxyl-3-oxide (PTIO), 1 μg/ml pertussis toxin (PTX), 50 μm l-NAME, 50 μm l-NIL, 1 mm 8-bromo-cGMP (8Br-cGMP), and 100 μm S 
	-nitroso-N 
	-acetyl-dl-penicillamine (SNAP).
Fig. 5. Effects of specific modulators on sevoflurane (SEVO)-mediated protection in myocytes exposed to 120 min of ischemia followed by hypoosmolar trypan blue. Trypan blue–positive myocytes are indicated as percentage of total viable myocytes before ischemia. CTL indicates control group and represents myocytes exposed to 120 min of ischemia alone. Data are mean ± SD. *P  < 0.001 versus  CTL. #P  not significant versus  CTL. †P  not significant versus  SEVO at 2 MAC. Abbreviations and concentrations of drugs used: 100 μm 8-sulfophenyl theophylline (STP), 100 μm 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), 100 μm adenosine (ADO), 0.1 μm prazosin (PRZ), 5 μm propranolol (PRO), 2 μm chelerythrine (CHE), 100 μm 5-hydroxydecanoate (5HD), 50 μm HMR-1098, 100 μm 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazole-1-oxyl-3-oxide (PTIO), 1 μg/ml pertussis toxin (PTX), 50 μm l-NAME, 50 μm l-NIL, 1 mm 8-bromo-cGMP (8Br-cGMP), and 100 μm S  -nitroso-N  -acetyl-dl-penicillamine (SNAP).
×
Fig. 6. Simplified scheme of signaling circuits potentially involved in the priming effect of volatile anesthetics on the mitochondrial KATP(mitoKATP) channel. Surface receptors may variably couple to different classes of G-protein subunits (Gαs, Gαi, Gαq, Gβγ). The main routes of activation by volatile anesthetics involve the Gαi protein–coupled adenosine receptor and the production of nitric oxide (NO), probably by modulation of NO synthase (NOS) activity. These two signaling pathways converge at the level of the protein kinase C (PKC), although alternative routes for NO could be operative as well. Lines with blunted ends (=) indicate inhibitors used in the present work. 8-bromo-cGMP (8Br-cGMP) partially mimics the effect of volatile anesthetics possibly by activation of the mitoKATPchannel via  protein kinase G (PKG) (dashed arrow). Inhibition of Gαi by pertussis toxin (PTX), inhibition of NOS by l-NIL and l-NAME, or scavenging of NO by PTIO, all partially reduce the myocyte protection of volatile anesthetics. The adrenergic receptor blockers prazosin (PRZ) and propranolol (PRO) do not affect the protection by isoflurane and sevoflurane.
Fig. 6. Simplified scheme of signaling circuits potentially involved in the priming effect of volatile anesthetics on the mitochondrial KATP(mitoKATP) channel. Surface receptors may variably couple to different classes of G-protein subunits (Gαs, Gαi, Gαq, Gβγ). The main routes of activation by volatile anesthetics involve the Gαi protein–coupled adenosine receptor and the production of nitric oxide (NO), probably by modulation of NO synthase (NOS) activity. These two signaling pathways converge at the level of the protein kinase C (PKC), although alternative routes for NO could be operative as well. Lines with blunted ends (=) indicate inhibitors used in the present work. 8-bromo-cGMP (8Br-cGMP) partially mimics the effect of volatile anesthetics possibly by activation of the mitoKATPchannel via 
	protein kinase G (PKG) (dashed arrow). Inhibition of Gαi by pertussis toxin (PTX), inhibition of NOS by l-NIL and l-NAME, or scavenging of NO by PTIO, all partially reduce the myocyte protection of volatile anesthetics. The adrenergic receptor blockers prazosin (PRZ) and propranolol (PRO) do not affect the protection by isoflurane and sevoflurane.
Fig. 6. Simplified scheme of signaling circuits potentially involved in the priming effect of volatile anesthetics on the mitochondrial KATP(mitoKATP) channel. Surface receptors may variably couple to different classes of G-protein subunits (Gαs, Gαi, Gαq, Gβγ). The main routes of activation by volatile anesthetics involve the Gαi protein–coupled adenosine receptor and the production of nitric oxide (NO), probably by modulation of NO synthase (NOS) activity. These two signaling pathways converge at the level of the protein kinase C (PKC), although alternative routes for NO could be operative as well. Lines with blunted ends (=) indicate inhibitors used in the present work. 8-bromo-cGMP (8Br-cGMP) partially mimics the effect of volatile anesthetics possibly by activation of the mitoKATPchannel via  protein kinase G (PKG) (dashed arrow). Inhibition of Gαi by pertussis toxin (PTX), inhibition of NOS by l-NIL and l-NAME, or scavenging of NO by PTIO, all partially reduce the myocyte protection of volatile anesthetics. The adrenergic receptor blockers prazosin (PRZ) and propranolol (PRO) do not affect the protection by isoflurane and sevoflurane.
×
Table 1. Percent Trypan Blue Positive Myocytes at Increasing Concentrations of Modulators after Exposure to 120 min of Ischemia
Image not available
Table 1. Percent Trypan Blue Positive Myocytes at Increasing Concentrations of Modulators after Exposure to 120 min of Ischemia
×